At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

US benchmark equity indexes closed lower Friday amid reports that President Donald Trump is set to implement tariffs on imports from Canada, Mexico and China. The Dow Jones Industrial Average dropped ...

U.S. stocks fall on Friday after the White House says Canada, Mexico and China tariffs will start Saturday. Still, major indexes finish January ahead.

The S&P 500 declined by 0.5% on Friday, Jan. 31, as investors digested the White House’s proposed tariffs on Canada, China, and Mexico.

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.

AbbVie’s ABBV 2024 revenue grew 4.6% on a constant currency basis, with 2025 guidance of 5.7% growth and new 2027 guidance for combined sales of immunology drug Skyrizi and Rinvoq of $31 billion (up ...

AbbVie (NYSE: ABBV) stock rose 4.2% after the drugmaker forecast 2025 profit above estimates, as strong sales of its newer ...

ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.

Looking ahead to 2025, AbbVie projects adjusted earnings per share between $12.12 and $12.32, reflecting strong confidence in its growth strategy. The company has significantly raised its long-term ...